Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Primary Malignant Central Nervous System Neoplasm|Locally Advanced Sarcoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Primary Malignant Central Nervous System Neoplasm|Metastatic Sarcoma|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8
Interventions: DRUG: Avapritinib
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)